Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

488
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
488
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

438
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
438
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

323
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A narrow developmental window defines PKN2's essential role in ventricular chamber morphogenesis.

Communications biology·2026
Same author

ASNA1 is essential for cardiac development and function by regulating tail-anchored protein stability and vesicular transport in cardiomyocytes.

PLoS genetics·2025
Same author

DNA damage and repair in cardiomyopathy: mechanisms and therapeutic opportunities.

American journal of physiology. Heart and circulatory physiology·2025
Same author

Ets1-regulated endothelial-secreted factors promote compact myocardial growth and contribute to the pathogenesis of ventricular non-compaction.

Cardiovascular research·2025
Same author

A Novel miniALPK3 Gene Therapy for ALPK3-Associated Cardiomyopathy.

Circulation·2025
Same author

Transcriptional readthrough at Atf4 locus suppresses Rps19bp1 and impairs heart development.

Cardiovascular research·2025

相关实验视频

Updated: Jan 11, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K

ALPK3心肌病:综合性综述与系统变异修复,机制和翻译.

Chien-Wei Chang1,2, Li Wang1, Zeyu Chen1

  • 1Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego (C.-W.C., L.W., Z.C., J.B., J.C.).

Circulation. Genomic and precision medicine
|November 12, 2025
PubMed
概括

在ALPK3的致病变体导致严重的心肌病. 双性功能丧失导致早期发病,而异性变体则导致过度缩性心肌病变. 基因替代和药物疗法对ALPK3心肌病有前途.

关键词:
心肌病心脏病变的发生.基因疗法的基因治疗.心脏衰竭是因为心脏衰竭.蛋白质激酶是一种蛋白质激酶.萨尔科梅雷斯 (sarcomeres) 是一种类型的恶性毒素.

更多相关视频

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.7K

相关实验视频

Last Updated: Jan 11, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.7K

科学领域:

  • 心血管遗传学 心血管遗传学
  • 分子心脏病学分子心脏病学
  • 遗传医学是一种遗传医学.

背景情况:

  • ALPK3 (α-蛋白激酶3) 的致病变体与心肌病症有关.
  • ALPK3 作为一种 Sarcomeric M-band 支架蛋白,对 Sarcomere 稳定性和蛋白质稳定性至关重要.
  • 疾病的严重程度与ALPK3变异的致死性相关.

研究的目的:

  • 综合审查和整理ALPK3变体和心肌病的临床和实验数据.
  • 阐明ALPK3相关心肌病的分子机制.
  • 评估ALPK3心肌病的治疗策略.

主要方法:

  • 在2025年6月9日之前,对同行评审报告和患者级数据进行系统的策划.
  • 临床前模型的分析,包括人类诱导的多能干细胞衍生的心肌细胞和小鼠模型.
  • 对治疗干预措施的审查,包括药理学药物和基因替代疗法.

主要成果:

  • 双性功能丧失ALPK3变体导致严重的,往往致命的,早期发作的心肌病与心脏外表现.
  • 异体蛋白切断ALPK3变体占成年人多性心肌病病例的1-4%,通常具有特定的多性模式和纤维化.
  • 失去ALPK3支架功能会导致MYOM移位,厚丝聚合和收缩功能障碍.
  • 用mavacamten (肌肉酶抑制剂) 和miniALPK3基因替代在小鼠模型中进行的治疗概念验证.

结论:

  • ALPK3心肌病是一种显著的遗传性疾病,其临床表现基于结合性而异.
  • 分子机制涉及由于ALPK3脚手架功能的丧失而破坏了sarcomeric蛋白质稳定.
  • ALPK3心肌病变是精准医学的一个可行的目标,基因替代和向疗法提供了潜在的疾病修饰治疗方法.